LENZ Therapeutics, Inc. commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, an FDA-approved aceclidine-based prescription eye drop for the treatment of presbyopia in adults. Company news centers on U.S. commercialization, product availability, financial results, prescribing and product-revenue updates, and consumer and professional education for the ophthalmic product.
Recurring LENZ developments also include regulatory submissions for VIZZ outside the United States, international licensing and commercialization partnerships, investor-conference participation, and safety or pharmacovigilance communications related to real-world product use. VIZZ is described by the company as a once-daily, preservative-free, single-dose vial product that uses a predominantly pupil-selective miotic mechanism to improve near vision.
LENZ (Nasdaq: LENZ) reported FDA approval of VIZZ (aceclidine 1.44%) on July 31, 2025 and initiated a commercial launch in October 2025 with broad availability expected mid‑Q4 2025. Early uptake includes >2,500 unique prescribers and >5,000 prescriptions filled through October 2025, plus 90% ECP awareness in October. The company reported pro forma cash, cash equivalents and marketable securities of approximately $324.0 million as of September 30, 2025 after utilizing $123.5M ATM capacity in October. LENZ recorded multiple partnership milestones totaling $10 million with CORXEL and an exclusive Canada license to Laboratoires Théa with >b>$70 million potential payments and tiered double‑digit royalties. Net loss for the nine months ended September 30, 2025 was $46.2 million.
LENZ Therapeutics (Nasdaq: LENZ) will report third quarter 2025 financial results and recent corporate highlights on Wednesday, November 5, 2025 at 8:30 a.m. EST via live webcast and conference call.
The company is a pharmaceutical firm commercializing VIZZ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine eye drop for presbyopia in adults. Participants may join by phone (Domestic: (800) 715-9871; International: (646) 307-1963) using access code 1685282. The live webcast is available on LENZ Therapeutics’ investor website and a replay will be posted for 30 days after the event.
LENZ Therapeutics (NASDAQ:LENZ) has announced the commercial availability of VIZZ™, their FDA-approved aceclidine-based eye drop treatment for presbyopia in adults. The product is being distributed as samples to eye care professionals nationwide, with commercial shipments starting in October through their ePharmacy partner.
VIZZ is notable as the first and only aceclidine-based eye drop approved for presbyopia, targeting a market of approximately 128 million adults in the United States. The treatment works through a pupil-selective miotic mechanism, achieving sub-2mm pupil size to improve near vision for up to 10 hours. Clinical trials showed 93% of participants achieved 20/40 or better near vision within 30 minutes.
LENZ Therapeutics (NASDAQ: LENZ), developer of VIZZ™ (aceclidine ophthalmologic solution) 1.44% for presbyopia treatment, announced its participation in multiple upcoming investor and medical conferences in September and October 2025.
The company will present at four major investor conferences: Citi's BioPharma Back to School Conference, Cantor Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and Morgan Stanley Global Healthcare Conference. All presentations will include live audio webcasts available on LENZ's website.
Additionally, at Academy 2025 Boston, two presentations will feature VIZZ: an oral podium presentation on efficacy and performance measures, and a poster presentation on optimal pupil size for miotic treatment of presbyopia.
LENZ Therapeutics (NASDAQ:LENZ) has received FDA approval for VIZZ™ (aceclidine ophthalmic solution 1.44%), the first and only aceclidine-based eye drop for treating presbyopia in adults. The product represents a breakthrough as the first once-daily solution providing up to 10 hours of improved near vision.
VIZZ works through a unique mechanism of action, contracting the iris sphincter muscle to achieve a sub-2mm pupil without causing myopic shift. The approval was supported by three Phase 3 studies (CLARITY 1, 2, and 3) involving 683 participants, demonstrating consistent efficacy within 30 minutes of application and good tolerability with no serious treatment-related adverse events.
Commercial launch is expected by mid-Q4 2025, with samples available as early as October 2025. The product addresses a significant market of approximately 128 million adults in the United States affected by presbyopia.
LENZ Therapeutics (NASDAQ:LENZ) reported Q2 2025 financial results and significant milestones in their presbyopia treatment program. The company's lead drug candidate LNZ100 has a PDUFA date of August 8, 2025, with FDA review progressing smoothly. LENZ has secured multiple international licensing deals worth over $195 million in potential payments plus double-digit royalties.
The company has completed hiring an 88-member sales force ready for immediate post-approval launch. Financial position remains strong with $209.6 million in cash as of June 30, 2025. Q2 net loss was $14.9 million ($0.53 per share), compared to $10.3 million ($0.40 per share) in Q2 2024.
LENZ Therapeutics (NASDAQ:LENZ) announced that its partner CORXEL Pharmaceuticals has submitted a New Drug Application (NDA) for LNZ100 to China's NMPA for presbyopia treatment. The submission is supported by successful Phase 3 JX07001 clinical trial results, where LNZ100 achieved its primary and secondary endpoints.
The NDA submission triggers the first milestone payment under the April 2022 licensing agreement, under which LENZ is eligible to receive up to $95.0 million in regulatory and sales milestones, plus tiered mid single-digit to low double-digit royalties on Greater China net sales.
LENZ Therapeutics (NASDAQ:LENZ) has entered into an exclusive license and commercialization agreement with Laboratoires Théa for LNZ100, a presbyopia treatment, in Canada. The deal includes over $70 million in upfront and milestone payments, plus double-digit royalties on net sales.
LNZ100, the first and only aceclidine-based eye drop for presbyopia, has a FDA PDUFA date of August 8, 2025. The FDA accepted the NDA in October 2024 and does not plan to hold an Advisory Committee Meeting. The treatment targets a condition affecting 1.8 billion people globally, including 128 million in the United States.
LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has announced its participation in three major upcoming investor conferences in June 2025:
- William Blair Growth Stock Conference on June 3 in Chicago (presentation at 1:40pm EDT)
- Jefferies Global Healthcare Conference on June 4-5 in New York City (presentation at 9:55am EDT)
- Goldman Sachs Global Healthcare Conference on June 9 in Miami Beach (fireside chat at 4:00pm EDT)
Live webcasts for the Jefferies and Goldman Sachs presentations will be available on LENZ's website, with replays accessible for 12 months. The company will also conduct one-on-one investor meetings at all three conferences.
LENZ Therapeutics (NASDAQ: LENZ) has entered into an exclusive license and commercialization agreement with Lotus Pharmaceutical for LNZ100, a presbyopia treatment eye drop, in Korea and Southeast Asia. The deal includes up to $125 million in upfront and milestone payments, plus double-digit royalties on future sales.
Lotus will have exclusive rights for LNZ100 in Korea, Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia, and Singapore. The agreement targets a market of over 100 million people affected by presbyopia in these regions. The FDA has already accepted LENZ's NDA for LNZ100 with a PDUFA date of August 8, 2025.